At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MGdrug
Likely dose
Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
In Brief
An observational study evaluating Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG for HIV-1-infection. Completed, enrolled 20 participants.
Detailed Summary
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
Countries--
CollaboratorsJanssen Scientific Affairs, LLC
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJun 2017
Primary CompletionApr 2018
Study CompletionMay 2018
TodayJul 2026
First PostedJun 26, 2017
Enrollment StartJan 1, 2017
Primary CompletionApr 18, 2018
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.0 years ago
Interventions
Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MGdrug